Evaluating the efficacy and safety of first-line immunotherapy for metastatic triple-negative breast cancer: a systematic review and network meta-analysis of randomized controlled trials with a focus on PD-L1 expression - Poll - MDSpire

Evaluating the efficacy and safety of first-line immunotherapy for metastatic triple-negative breast cancer: a systematic review and network meta-analysis of randomized controlled trials with a focus on PD-L1 expression

  • By

  • Yanxiao Sun

  • Longtao Zhang

  • Dong Guo

  • June 5, 2026

Share

Original Source(s)

Evaluating the efficacy and safety of first-line immunotherapy for metastatic triple-negative breast cancer: a systematic review and network meta-analysis of randomized controlled trials with a focus on PD-L1 expression

  • by Yanxiao Sun, Longtao Zhang, Dong Guo

  • June 5, 2026

Related Content

The efficacy of angiogenesis inhibitors combined with chemotherapy in advanced breast cancer: a systematic review and meta-analysis

Polymorphous low-grade neuroepithelial tumor of the young: a case report

Targeting mitochondria as a potential therapeutic strategy against radioresistance in cancer